Merck (MRK) Announces FDA Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection

Go back to Merck (MRK) Announces FDA Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
Merck & Co. (NYSE: MRK) Delayed: 149.54 -3.56 (2.33%)
Previous Close $153.10    52 Week High $65.46 
Open $149.53    52 Week Low $47.97 
Day High $152.08    P/E 101.73 
Day Low $149.02    EPS $1.47 
Volume 8,528,140